All In Biotech

Drug Trial Radar · NCT00553631

Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease

A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

34

Actual

Start

Jan 29, 2008

Primary completion

May 5, 2009

Study completion May 5, 2009

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Nov 5, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to imiglucerase in treatment naive patients with type 1 Gaucher disease.

Conditions

  • Gaucher Disease, Type 1

Interventions

  • velaglucerase alfaBiological

    IV infusion, 60 U/kg every other week for 9 months

  • imigluceraseBiological

    IV infusion, 60 U/kg every other week for 9 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group.Time frame: Baseline to Month 9

Locations

11 sites in 9 countries. Site status is shown where the registry gives one.

  • Duke Children's Hospital & Health Center

    Durham, North Carolina

  • Your Health S.A.

    Buenos Aires, Argentina

  • All India Institute of Medical Sciences

    New Delhi, India

  • KEM Hospital Research Centre

    Pune, India

  • Malabar Institute of Medical Sciences Ltd.

    Calicut, Kerala, India

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Sociedad Espanola de Socorros Mutuos

    Asunción, Paraguay

  • National Research Center for Haematology

    Moscow, Russia

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • La Rabta Hospital

    Tunis, Tunisia

  • The Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.